+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

From
ROS1 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

ROS1 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
HAVCR2 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

HAVCR2 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Tau protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Tau protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A3 Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Growth Hormone (GH) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Growth Hormone (GH) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
Adenosine A3 Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A3 Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Carnitine Palmitoyltransferase I (CPT 1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Carnitine Palmitoyltransferase I (CPT 1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Muscarinic Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Muscarinic Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Adenosine A2 Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A2 Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Adenosine A2A Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A2A Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A2A Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucagon Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more